Search for Terms or Answers
Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.
Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE. A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016.
Dr. Jack Cush interviews Professor Edward Keystone, MD (University of Toronto) on the origins and science behind the 60/40/20 benchmark and outcomes in rheumatoid arthritis.
The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis.
Little is known about the safety of newer biologic use during pregnancy, especially in patients who either conceive while on a biologic or must remain on a biologic during pregnancy (often the case with IBD and inflammatory arthritis).
In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials.
It is almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under emergency use authorization (EUA). The question still being asked is whether the vaccine is safe for people with lupus?
Surely you’ve seen this or been plagued by this patient, one that is not doing well, in need of a new regimen; you outline it, timeline it, define the side effects and send them off with a new prescription..
My research shows that up to 50% of rheumatologists measure something in the course of their daily assessments, and RAPID3 is most popular, being employed by 31% of rheumatologists.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
